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Abstract
Chronic fatigue syndrome (CFS) is a clinically defined illness estimated to affect millions of people worldwide causing
significant morbidity and an annual cost of billions of dollars. Currently there are no laboratory-based diagnostic methods
for CFS. However, differences in gene expression profiles between CFS patients and healthy persons have been reported in
the literature. Using mRNA relative quantities for 44 previously identified reporter genes taken from a large dataset
comprising both CFS patients and healthy volunteers, we derived a gene profile scoring metric to accurately classify CFS
and healthy samples. This metric out-performed any of the reporter genes used individually as a classifier of CFS. To
determine whether the reporter genes were robust across populations, we applied this metric to classify a separate blind
dataset of mRNA relative quantities from a new population of CFS patients and healthy persons with limited success.
Although the metric was able to successfully classify roughly two-thirds of both CFS and healthy samples correctly, the level
of misclassification was high. We conclude many of the previously identified reporter genes are study-specific and thus
cannot be used as a broad CFS diagnostic.
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Introduction
Chronic fatigue syndrome (CFS) is a clinically defined illness
with a broad range of symptoms including severe and debilitating
fatigue, muscle pain, sleep disruption, difficulties with concentra-
tion, memory impairment and headaches. It is estimated to affect
0.4% of the population in Europe and North America [1] and cost
$9 billion annually in lost productivity in the USA alone [2]. The
cause and pathogenesis of CFS remain poorly understood,
although various infectious triggers have been proposed.
There are currently no specific laboratory-based tests that provide
a robust diagnosis of CFS. However, previous studies indicate
significant differences in the patterns of gene expression in peripheral
blood leukocytes between patients with CFS and healthy individuals
[3–10]. Although many of these studies have not detailed predictive
sets of genes that could be used to make a diagnosis of CFS on the
basis of their expression, we showed previously that the expression
levels of 88 ‘‘CFS reporter genes’’, identified using microarrays, could
assign individuals to CFS disease or healthy control groups following
quantitative PCR of PBMC RNA [7,8].
Microarray analysis has been used frequently to identify groups of
genes associated with various diseases, including infectious diseases
[11], autoimmune diseases and cancer [12]. In such studies, a
microarray dataset featuring tens of thousands of genes is
computationally reduced to several hundred genes found to be
significantly differentially expressed between healthy and diseased
individuals, or between different stages of disease. Computational
methods, such as support vector machines (e.g. [13]), artificial neural
networks (e.g. [14]) and simple selective naı¨ve Bayes classifiers [15],
are able to identify such gene sets for disease classification. These
methods require training the underlying statistical models on data
representative of diseased and healthy phenotypes in order to make
such predictions. Ideally, models are trained on a well-characterised
dataset and evaluated using a separate, preferably blinded, test set
consisting of new samples from diseased and healthy individuals. The
use of different non-array based methods for quantification of gene
expression, such as reverse transcription polymerase chain reaction
(RT-PCR) is also desirable. On this basis, a gene profile can be
formally assessed as a multiplex diagnostic tool.
Here, we have undertaken such an analysis to determine the
predictive power of our ‘CFS signature genes’ identified previously
[7,8]. We have assessed the CFS disease predictive genes in the
original study data and in a new blinded sample set of CFS disease
and healthy control samples. We show, using a variety of methods,
that these genes do not identify robustly patients with CFS disease.
Results
CFS class prediction using a 44 gene classifier
To develop a robust CFS diagnostic metric, we used as a
training set the mRNA relative quantities (RQ, defined as
22DDCT) for the 44 most discriminating reporter genes identified
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previously by us [7,8] (Table S1). The data were normalised to
GAPDH and to a calibrator sample. Initially, we assessed the
ability of each of the individual reporter genes to be used as an
accurate predictor of CFS disease in this dataset of PBMC gene
expression, determined for 56 patients suffering from CFS and 75
healthy volunteers.
Figure 1. A boxplot illustrating the distribution of log2(RQ) values for each of the reporter genes in the training set. Distributions for
CFS samples are shown in red, healthy samples in white. The boxes represent the inter-quartile range (25–75%) of the data with the median being
shown as a solid horizontal line within each box. Whiskers extend to 1.5 times the inter-quartile range. The data is log2 scaled and outliers omitted for
purposes of clarity.
doi:10.1371/journal.pone.0016872.g001
Figure 2. ROC curves obtained when using (A) ARL4C and (B) NUFIP2 as CFS predictors on the training set. The graphs are coloured
according to the scale bar on the right hand y-axes to indicate the RQ value cut-offs associated with each pair of sensitivity and specificity values at
that particular point in the ROC curve. The AUCs were found to be: (A) 0.94 and (B) 0.67.
doi:10.1371/journal.pone.0016872.g002
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For each of the 44 reporter genes, we assessed the distribution of
RQ values, finding that each of the genes was expressed at higher
levels in the CFS samples than controls (Figure 1). In some cases,
the RQ values of the reporter genes were clearly separate and the
mean RQ differed significantly between CFS and controls, for
example ANAPC11. For other classifier genes, although the mean
RQ values differed significantly between CFS and control samples,
the separation of the individual RQ values was not so distinct, for
example MRRF.
For each of the genes we performed receiver operator curve
(ROC) analysis, using different RQ value cut-offs to produce ROC
curves and a corresponding assessment of sensitivity, specificity, true
Figure 3. Area under the curve (AUC) values for each of the reporter genes when used as CFS predictors on the training set. All
perform better than random (AUC=0.5).
doi:10.1371/journal.pone.0016872.g003
Assessment of Gene Expression Classifier for CFS
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e16872
Assessment of Gene Expression Classifier for CFS
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e16872
and false positive rates (TPR, FPR) for each gene. We used the
results of the ROC analyses to identify an RQ value cut off for each
gene that maximised the true positive, and minimised the false
positive, classification of CFS samples. A sample was classified as
CFS-positive if its RQ value was greater than the calculated cut-off.
Consistent with the distribution of RQ values for each gene
(Figure 1) the area under the curve (AUC) from the ROC analysis for
the 44 reporter genes varies substantially, from 0.67 to 0.94 (Figures 2,
3 and Table S2). ARL4C was found to be the best CFS predictor
(AUC = 0.94), whilst NUFIP2 performs poorly (AUC = 0.67); thus,
NUFIP2 performs only marginally better than a random predictor
(AUC = 0.5). Consequently, the individual 44 reporter genes vary
considerably in their ability to predict CFS in the training set
accurately, although all perform better than a random predictor
(Figure 3). Those with high AUCs yield fewer false positives at low
RQ cut-offs and fewer false negatives at higher RQ cut-offs.
Using individual genes as classifiers is often problematic due to
missing data, where gene expression levels are not available for all
patients and individual variation of single gene expression
confounds predictive power. Thus, in principle, no single reporter
gene would be able to classify CFS accurately across all samples.
We therefore explored the data structure of the 44 gene expression
set using unsupervised hierarchically clustering of the PCR-
derived RQ gene expression levels in the training set using
Euclidean distance (Figure 4). Although there is clearly an
underlying structure to the data, with many of the CFS and
control samples clustering in distinct groups, there is also clearly
overlap between the two groups. This is most likely due to missing
data and occasionally large RQ outliers skewing the clustering.
Consistent with this observation, the 44 reporter genes could not
produce a CFS classifier using support vector machines by training
on a subset of the training set and assessing the predictive power
on a separate subset (data not shown). To minimise the effect of
missing gene expression levels in each sample, we filtered the
training set to include only samples for which there were at least 22
different RQ gene expression values (i.e. 50% of the reporter
genes). However, this did not improve the ability to predict CFS
cases using hierarchical or k-means clustering, or SVMs.
Gene Profile Score Metric
Because standard clustering and classification methods were
unable to classify the training set, we developed a scoring metric
based around a gene-profiling approach. For each sample, a gene
profile was generated using a binary classification of CFS or
control for each reporter gene: a sample with a RQ value greater
than the defined gene specific cut-off corresponding to a 5% false
positive rate determined from the earlier ROC analysis was
assigned a ‘1’ (‘‘present’’), or otherwise a ‘0’ (‘‘absent’’). Any
missing data values were assigned a ‘0’. The per gene score is
summed over the 44 genes, resulting in a profile score of between 0
and 44 for each sample. Samples with high scores should be over
represented for CFS disease whilst samples with low scores all
should be healthy controls.
We assessed the ability of this metric to differentiate between
CFS and healthy samples in the training set again using ROC
analysis on the profile score, obtaining true and false positive rates
for a range of profile score cut-offs (Figure 5). This method results
in an AUC of 0.95, with 47 CFS (84%) and 72 healthy controls
(96%) correctly predicted in the 131 sample training set. This
therefore represents a better predictor of CFS than any of the
genes used individually (Figure 3).
We applied this gene profile score metric to analyse a blind
study dataset, selecting a profile score cut-off of 5, above which
samples were classed as CFS disease and equal to or below were
classed as healthy controls. At this level of score threshold, the
training set gave a FPR of 5%. Under these criteria, our predictor
Figure 5. ROC curves for the gene profile score metric using a false positive rate (FPR) on the training set of (A) 5% and (B) 10%. For
more detail, see Materials and Methods. The graph is coloured to indicate the gene profile score cut-offs associated with each pair of true and false
positive rates at that particular point in the ROC curve. The range of profile cut-off scores are coloured on the right hand y-axes of each graph. The
profile score cut-offs used to classify the test set were derived by selecting scores yielding FPR’s of (A) 5% and (B) 10%, as indicated by the dashed
lines.
doi:10.1371/journal.pone.0016872.g005
Figure 4. Hierarchical clustering across samples of RQ values from the training set by Euclidean distance with average linkage.
Reporter genes are arranged in columns, samples in rows. Missing values are shown in grey.
doi:10.1371/journal.pone.0016872.g004
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assigned from the 128 blinded samples, 32 CFS positive samples,
of which 22 were true-positives (69%) and 10 were false-positives
(31%) (Table 1). Correspondingly, it predicted 96 healthy samples
of which 51 were true negatives (53%) and 45 were false negatives
(47%). Overall, this resulted in 73 (58%) correct classifications
(TP+TN), based on our gene expression scoring metric. An
empirical assessment of the blinded test set based on expert
assessment of the RQ values resulted in the correct class prediction
of 79 of 128 samples (61%).
To determine if the predictive power that was evident in the
training data was lost on the test data due to a subset of poorly
performing genes we looked at the number of correctly predicted
samples per gene (Figure 6). This showed that except for 3 genes
(MRPL23, PKN1 and ARL4C) all other genes had significantly
lower predictive power in the test set. Although a number of reporter
genes are good CFS predictors in the training set, the majority
perform no better than random, 32 of the 44 making more incorrect
than correct predictions on the test set (Tables S3, S4). Those that are
good CFS predictors in the training set are not necessarily good
predictors in the test set: there is no correlation between the number
of correct predictions made by each reporter gene individually across
the two data sets (Pearson’s correlation coefficient = 0.07).
To determine if the calibrator reference sample confounded the
RQ-based analysis we investigated the properties of normalized
real time DCT values. Performing ROC analysis and generating
profile scores for the DCT values, we found no significant
difference in predictive outcome for the 44 reporter genes in terms
of their ability to classify CFS and healthy samples, either when
used as individual classifiers or by combining them to generate
profile scores (Figure S1, Tables S5, S6).
For the training set, mean RQ values are significantly higher in
CFS than healthy samples for each of the 44 reporter genes (Welch
2-sample t-test, P,0.01). However, no significant difference is
observed between the means for any of these genes in the test set
(Welch 2-sample t-test, all P.0.01). Thus, although the reporter
genes could be used (either by profile score or, to a lesser extent,
individually) to classify CFS in the original study, they are not
robust in a new sample population.
Discussion
Here we have assessed the ability of a proposed 44 gene
classifier [8] to discriminate between CFS patients and healthy
control individuals. This classifier was able to discriminate
correctly between CFS and healthy control samples in 95% of
the training samples. However, when assessed on a new, blinded
128 sample test set only 58% of samples were predicted correctly.
Importantly, a high number of false-positive predictions were
made, with 31% of CFS-positive predictions being from healthy
volunteers. In addition, a high number of false negative predictions
were made, 57% of the CFS samples being predicted as healthy
controls. Therefore, with the methods used here we cannot predict
CFS disease based on the analysis of expression of 44 classifier
genes in the peripheral blood.
There may be several reasons for the poor performance on the
blinded test set for what, as far as the training set is concerned,
would otherwise be considered a good predictive metric. Firstly,
the low 5% FPR per gene in the development of cut-off scores for
the scoring metric may have resulted in over-fitting to the training
set. This seems unlikely, however, as similar results were observed
based on a more relaxed training set FPR of 10% with the training
set still producing a classifying AUC of 0.94 (Figure 5). Although
roughly two-thirds (43/67, 64%) of the CFS samples from the
blinded test set were classified correctly using a profile score cut-off
corresponding to a FPR of 10%, the rate of misclassification was
Figure 6. Percentage of predictions made correctly by each of the reporter genes using cut-offs corresponding to a FPR of 5% on
the training set (blue) and the test set (red).
doi:10.1371/journal.pone.0016872.g006
Table 1. The performance of the gene profile score metric in
classifying samples in the test set.
Method Positive Negative
5% FPR True text 22 51
False text 10 45
10% FPR True text 43 37
False text 24 24
Cut-offs were used on the test set corresponding to false positive rates (FPR) of
5% and 10% on the training set.
doi:10.1371/journal.pone.0016872.t001
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higher (24/67, 36%; Table 1). Secondly, there may be
fundamental biological differences between the training and test
set due to for example, population stratification, age, onset of CFS
or other factors which confound both clustering and gene-profiling
approaches. In the worst case, the 44 reporter genes may not be
representative beyond the small study in which they were
identified [7].
The determination of microarray study specific gene classifiers has
lead to the proposed identification of various CFS reporter genes,
based on microarray analysis of gene expression [3–10]. There is little
overlap in the gene sets, a reflection of the difference between studies.
Larger CFS microarray studies, together with analysis by comparison
with different control groups, may help in identify CFS disease-
classifying gene sets. Alternatively, a meta-analysis of existing CFS
data sets would provide a valuable extension with the potential to
identify gene expression signatures for formal assessment as disease
classifiers in new samples, as outlined here.
Materials and Methods
Datasets
Two datasets of quantitative real time RT-PCR values pre-
processed as mRNA relative quantities (RQ), defined as 22DDCT
for 44 reporter genes were used in this study. The first dataset, was
generated from PBMC samples taken from 57 CFS patients and
75 healthy volunteers and had previously been reported [8]. This
was used as a training set. The second study was from a blinded
study and was used as a test set. This comprised PBMC samples
from 64 CFS patients and 64 healthy volunteers. This sample set
was blinded and the disease classification was not assessed until the
classes were predicted computationally. The data for the blinded
study was collected via clinical questionnaires as outlined
previously [8]. The patients were provided with paper copies for
completion at home and subsequent return by post to the clinical
centre. Data from the questionnaires was collated and used for
clinical characterisation. The diagnosis of CFS was based on the
Fukuda criteria and this diagnosis was made by CFS clinical
experts. The blinded study was approved by the Wandsworth
Research Ethics Committee, St George’s Hospital, London, SW17
0QT. Verbal consent was given by all subjects for their
information to be stored and used for this study.
Analysis
Hierarchical and k-means clustering of RQ values was
performed using the TIGR MeV software suite [16]. Support
vector machines (SVM) were also created using MeV, using the
training set to train the SVM and the test set to evaluate the
accuracy of SVM classification.
Receiver operator curve (ROC) analysis was performed using
the ROCR library [17] within R/BioConductor [18]. Individual
reporter genes were used as CFS predictors for the training set, the
corresponding sensitivity, specificity, true and false positive rates
were determined for all possible RQ cut-offs (from the smallest to
largest RQ value). Areas under the curve were determined for
each of the reporter genes as a measure of prediction accuracy.
The same procedure was used to evaluate the gene profile score
metric, outlined below.
Gene profile score metric
A gene profile score metric was generated as follows. Firstly, RQ
cut-offs were determined for each reporter gene such that the
associated false-positive rate of CFS prediction in the training set,
using that gene alone, was 5%. These cut-offs were used to create
binary profiles (44 digits in length) for each sample, with a ‘1’
indicating that particular sample had an RQ greater than the cut-
off and a 0, otherwise (either a lower RQ or a missing value).
The norm of the profile was then calculated by summing all 44
scores to give the ‘‘gene profile score’’. Thus, if the reporter genes
are accurate predictors of CFS, samples from CFS patients would
yield a higher profile score than those from healthy volunteers.
The gene profile score metric itself was evaluated using ROC
analysis using the training set. From this analysis. a profile score
cut-off was generated at which level of the metric yielded a 5%
false positive rate when classifying the training set. Profile scores
were then generated for the blinded test set and samples were
classified as ‘‘CFS’’ or ‘‘healthy’’ according to this cut-off.
We assessed the effect of altering the RQ cut-off score such that
the false positive rate for both individual reporter genes and for the
resultant gene profile score metric was 10% in terms of classifying
CFS and healthy samples in the training set.
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